01
eNOS-KO modelNO-related recovery
Creatinine-normalized urinary nitrite/nitrate increased approximately 635%, while TxB₂ decreased approximately 89%.
VASCULAR BIOENGINEERING · JEJU, KOREA
Restoring vascular signaling
beyond enzymatic limits.
Baryeo Innovation develops SST, an investigational material platform supported by preclinical evidence across NO-related chemistry, oxidative stress and vascular responsiveness.
+635%Urinary NOx
−89%Thromboxane B₂
11.0 → 69.2 µMSHR nitrite
>18 hVascular response
OBSERVED PRECLINICAL EVIDENCE
Measured biology. Carefully bounded claims.
Our development strategy starts with reproducible observations—not assumptions about mechanism.
02
SHR modelRedox & vascular response
Serum nitrite increased from 11.0 to 69.2 µM; MDA decreased from 9.8 to 3.8 µM; ACh vasorelaxation recovered to pD₂ 7.95.
03
DurabilitySustained functional signal
Improved vascular sensitivity was observed for more than 18 hours in the preclinical model.
THE SST PLATFORM
A complementary vascular-signaling candidate.
SST does not carry oxygen and is not intended to replace hemoglobin or artificial oxygen carriers. We are evaluating whether it can support the vascular environment in settings where endogenous signaling is impaired.
SST is Baryeo Innovation’s working platform name. We use it without expanding it into an unverified mechanistic acronym.
ValidatedNOx, TxB₂, MDA and vasorelaxation outcomes
InvestigationalMaterial-mediated and eNOS-independent working model
NextExternal replication and defined combination studies
SST · SCIENTIFIC BOUNDARY
Evidence first. Hypotheses clearly labeled.
Investigational material platform
A hydrated, material-based candidate being studied for its association with NO-related chemistry and vascular homeostasis.
Preclinical functional response
Independent models showed changes in NOx, TxB₂, MDA and acetylcholine-induced vasorelaxation. These are measured observations, not clinical claims.
Mechanism and translation
Direct molecular causality, human efficacy, optimal dosing and combination benefit with oxygen carriers require prospective validation.
PARTNER STUDY
One clear question. Three blinded arms.
A bounded pilot can determine objectively whether SST provides additive vascular or perfusion benefit without impairing oxygen-carrier performance.
01Matched control
02Oxygen carrier
03Oxygen carrier + SST
MAP / SVR · microvascular perfusion · tissue oxygenation · methemoglobin · NOx / cGMP · safety
BARYEO INNOVATION CO., LTD.
From Jeju to global research partnerships.
We collaborate with academic laboratories, oxygen-carrier developers and translational research teams to turn distinctive preclinical signals into reproducible development programs.